Glucaric acid

Glucaric acid is a lipid of Fatty Acyls (FA) class. Glucaric acid is associated with abnormalities such as Consumption-archaic term for TB and furuncle. The involved functions are known as Oxidation, Mutation, Process, Cell Growth and Anabolism. Glucaric acid often locates in BL21, Clone and host. The associated genes with Glucaric acid are MIOX gene, ISYNA1 gene, Genome and Candidate Disease Gene. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of Glucaric acid, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Glucaric acid?

Glucaric acid is suspected in and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Glucaric acid

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Insulin Resistance D007333 99 associated lipids
Brain Ischemia D002545 89 associated lipids
Atherosclerosis D050197 85 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Hyperlipidemias D006949 73 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Parkinson Disease D010300 53 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Precancerous Conditions D011230 48 associated lipids
Leukemia P388 D007941 43 associated lipids
Occupational Diseases D009784 42 associated lipids
Hypotension D007022 41 associated lipids
Adenoma D000236 40 associated lipids
Chemical and Drug Induced Liver Injury D056486 39 associated lipids
Heart Failure D006333 36 associated lipids
Epilepsy D004827 35 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Hyperplasia D006965 34 associated lipids
Micronuclei, Chromosome-Defective D048629 33 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Liver Diseases D008107 31 associated lipids
Kidney Diseases D007674 29 associated lipids
Kidney Neoplasms D007680 29 associated lipids
Alcoholism D000437 27 associated lipids
Hyperinsulinism D006946 27 associated lipids
Anemia D000740 21 associated lipids
Myocardial Infarction D009203 21 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Esophageal Neoplasms D004938 20 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Myocardial Reperfusion Injury D015428 20 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Peritoneal Neoplasms D010534 16 associated lipids
Hypercalcemia D006934 13 associated lipids
Liver Diseases, Alcoholic D008108 13 associated lipids
Vitamin D Deficiency D014808 13 associated lipids
Critical Illness D016638 13 associated lipids
Hypocalcemia D006996 12 associated lipids
Carbon Tetrachloride Poisoning D002252 12 associated lipids
Hepatitis D006505 11 associated lipids
Per page 10 20 50 100 | Total 85

PubChem Associated disorders and diseases

What pathways are associated with Glucaric acid

Lipid pathways are not clear in current pathway databases. We organized associated pathways with Glucaric acid through full-text articles, including metabolic pathways or pathways of biological mechanisms.

Related references are published most in these journals:

Pathway name Related literatures
Loading... please refresh the page if content is not showing up.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Glucaric acid?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Glucaric acid?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Glucaric acid?

There are no associated biomedical information in the current reference collection.

What genes are associated with Glucaric acid?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Glucaric acid?

Knock-out

Knock-out are used in the study 'Evolution-guided optimization of biosynthetic pathways.' (Raman S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Glucaric acid

Download all related citations
Per page 10 20 50 100 | Total 1061
Authors Title Published Journal PubMed Link
Sanai T et al. Effect of saccharated ferric oxide and iron dextran on the metabolism of phosphorus in rats. 2005 J. Lab. Clin. Med. pmid:16025088
Bontchev RP and Moore RC Crystal structure and aqueous solubility of ammonium D-glucarate. 2005 Carbohydr. Res. pmid:16043161
Wood DM et al. Hepatocellular damage following therapeutic intravenous iron sucrose infusion in a child. 2005 Ther Drug Monit pmid:16044093
Macdougall IC and Roche A Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections. 2005 Am. J. Kidney Dis. pmid:16112047
Perek N et al. MRP-1 protein expression and glutathione content of in vitro tumor cell lines derived from human glioma carcinoma U-87-MG do not interact with 99mTc-glucarate uptake. 2005 Cancer Biother. Radiopharm. pmid:16114987
Zager RA Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy. 2005 Kidney Int. pmid:16164630
Erichsen K et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. 2005 Scand. J. Gastroenterol. pmid:16165718
Strolin Benedetti M et al. Induction of endogenous pathways by antiepileptics and clinical implications. 2005 Fundam Clin Pharmacol pmid:16176329
St Peter WL et al. Trends in intravenous iron use among dialysis patients in the United States (1994-2002). 2005 Am. J. Kidney Dis. pmid:16183420
Ayotte P et al. Biomarker measurements in a coastal fish-eating population environmentally exposed to organochlorines. 2005 Environ. Health Perspect. pmid:16203240
Ozdemir A et al. Relationship between iron replacement and hepatic functions in hepatitis C virus-positive chronic haemodialysis patients. 2005 Nephrology (Carlton) pmid:16221090
Spiegel K et al. Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes. 2005 J. Appl. Physiol. pmid:16227462
Johnson G et al. (99m)Tc-glucarate imaging for the early detection of infarct in partially reperfused canine myocardium. 2006 Eur. J. Nucl. Med. Mol. Imaging pmid:16237571
Aime S et al. para-Hydrogenation of unsaturated moieties on poly(lysine) derived substrates for the development of novel hyperpolarized MRI contrast agents. 2005 Org. Biomol. Chem. pmid:16240012
Glassman E Oral iron therapy with ferrous fumarate and polysaccharide iron complex. 1992 ANNA J pmid:1627011
Georgopoulos D et al. Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]. 2005 Crit Care pmid:16277712
Schröder O et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study. 2005 Am. J. Gastroenterol. pmid:16279906
Sengölge G et al. Intravenous iron therapy: well-tolerated, yet not harmless. 2005 Eur. J. Clin. Invest. pmid:16281958
pmid:16286429
Tutor-Crespo MJ et al. Effect of antiepileptic drugs on the urinary excretion of porphyrins in non-porphyric subjects. 2005 J. Pharmacol. Sci. pmid:16314692
Schaller G et al. Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients. 2005 Kidney Int. pmid:16316358
Van Wyck DB et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. 2005 Kidney Int. pmid:16316362
Laman CA et al. Parenteral iron therapy: a single institution's experience over a 5-year period. 2005 J Natl Compr Canc Netw pmid:16316614
Anemia during pregnancy and in the postpartum: intravenous iron therapy revisited. 2005 Eur. J. Obstet. Gynecol. Reprod. Biol. pmid:16360535
Govan AD and Scott JM Intravenous iron in the treatment of anemia of pregnancy. 1949. 2005 Eur. J. Obstet. Gynecol. Reprod. Biol. pmid:16360540
Karkouti K et al. Intravenous iron and recombinant erythropoietin for the treatment of postoperative anemia. 2006 Can J Anaesth pmid:16371604
Zheng H et al. Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects. 2006 Kidney Int. pmid:16395269
pmid:16417257
Hoyle VR et al. Studies on the biochemical effects of the aldose reductase inhibitor 2,7-difluorospirofluorene-9,5'-imidazolidine-2',4'-dione (Al 1576, HOE 843). Detection of D-glucaric and D-glucuronic acid excretion by high resolution 1H and 13C NMR spectroscopy. 1992 Biochem. Pharmacol. pmid:1642638
Anbu AT et al. Low incidence of adverse events following 90-minute and 3-minute infusions of intravenous iron sucrose in children on erythropoietin. 2005 Acta Paediatr. pmid:16431410
Cançado RD et al. [Evaluation of the efficacy of intravenous iron III-hydroxide saccharate for treating adult patients with iron deficiency anemia]. 2005 Nov-Dec Rev Assoc Med Bras (1992) pmid:16444338
pmid:16504354
Brown SD et al. A gold standard set of mechanistically diverse enzyme superfamilies. 2006 Genome Biol. pmid:16507141
pmid:16522172
Koutroubakis IE et al. Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anaemia: a pilot study. 2006 Eur J Gastroenterol Hepatol pmid:16538115
Agarwal R Proinflammatory effects of iron sucrose in chronic kidney disease. 2006 Kidney Int. pmid:16609688
Muñoz M et al. Role of parenteral iron in transfusion requirements after total hip replacement. A pilot study. 2006 Transfus Med pmid:16623920
Sudan C et al. Ubiquitous presence of beta-glucuronidase (GUS) in plants and its regulation in some model plants. 2006 Planta pmid:16652220
Strack D et al. Enzymic synthesis of caffeoylglucaric Acid from chlorogenic Acid and glucaric Acid by a protein preparation from tomato cotyledons. 1987 Plant Physiol. pmid:16665274
Guz G et al. Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients. 2006 Nephrol. Dial. Transplant. pmid:16762960
Barton Pai A et al. Non-transferrin-bound iron is associated with enhanced Staphylococcus aureus growth in hemodialysis patients receiving intravenous iron sucrose. 2006 Am. J. Nephrol. pmid:16809897
Coletta AP et al. Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC-HF and KW-3902. 2006 Eur. J. Heart Fail. pmid:16887387
Schiesser D et al. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. 2006 Nephrol. Dial. Transplant. pmid:16891647
Kato M et al. Tetranuclear copper(II) complexes bridged by alpha-D-glucose-1-phosphate and incorporation of sugar acids through the Cu4 core structural changes. 2006 Inorg Chem pmid:16903719
Carlini RG et al. Apoptotic stress pathway activation mediated by iron on endothelial cells in vitro. 2006 Nephrol. Dial. Transplant. pmid:16957011
Agarwal R Is i.v. iron really superior in CKD patients not on dialysis? 2006 Kidney Int. pmid:16957750
Davey CL et al. Esterification of select polyols with D-glucaric acid as model reactions for esterification of starch. 2006 Carbohydr. Res. pmid:16973136
Bolger AP et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. 2006 J. Am. Coll. Cardiol. pmid:16979010
García-Erce JA et al. Perioperative intravenous iron preserves iron stores and may hasten the recovery from post-operative anaemia after knee replacement surgery. 2006 Transfus Med pmid:16999756
Bhandal N and Russell R Intravenous versus oral iron therapy for postpartum anaemia. 2006 BJOG pmid:17004982
Yaoita H et al. Localization of technetium-99m-glucarate in zones of acute cerebral injury. 1991 J. Nucl. Med. pmid:1704054
Eiselt J et al. The effect of intravenous iron on oxidative stress in hemodialysis patients at various levels of vitamin C. 2006 Blood Purif. pmid:17077626
Sirken G et al. Association of different intravenous iron preparations with risk of bacteremia in maintenance hemodialysis patients. 2006 Clin. Nephrol. pmid:17140164
Breborowicz A et al. Iron sucrose induced morphological and functional changes in the rat kidney. 2006 Transl Res pmid:17145571
pmid:17198668
Watanabe S et al. alpha-ketoglutaric semialdehyde dehydrogenase isozymes involved in metabolic pathways of D-glucarate, D-galactarate, and hydroxy-L-proline. Molecular and metabolic convergent evolution. 2007 J. Biol. Chem. pmid:17202142
Hörl WH Iron therapy for renal anemia: how much needed, how much harmful? 2007 Pediatr. Nephrol. pmid:17206511
pmid:17226954
Kim YT et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. 2007 Gynecol. Oncol. pmid:17234260
Olas B et al. Protective effects of D-glucaro 1,4-lactone against oxidative/nitrative modifications of plasma proteins. 2007 Nutrition pmid:17234507
pmid:17264097
Izuel Rami M et al. [Budget impact analysis of a blood saving program for urgent traumatological surgery]. 2007 Med Clin (Barc) pmid:17266885
Breymann C et al. Milk iron content in breast-feeding mothers after administration of intravenous iron sucrose complex. 2007 J Perinat Med pmid:17302514
Pai AB et al. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. 2007 Pharmacotherapy pmid:17316146
pmid:17322190
Marsillach J et al. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia. 2007 Clin. Exp. Pharmacol. Physiol. pmid:17324148
George P et al. Coronary artery vasospasm with iron sucrose. 2007 Nephrol. Dial. Transplant. pmid:17327282
Beck-da-Silva L et al. Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. 2007 J. Card. Fail. pmid:17338998
Ranfaing E [Treatments of the martial deficiencies: preparations available in France]. 2006 Nephrol. Ther. pmid:17373280
Sane R et al. Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate. 2007 Pharmacotherapy pmid:17381390
Iversen C et al. The taxonomy of Enterobacter sakazakii: proposal of a new genus Cronobacter gen. nov. and descriptions of Cronobacter sakazakii comb. nov. Cronobacter sakazakii subsp. sakazakii, comb. nov., Cronobacter sakazakii subsp. malonaticus subsp. nov., Cronobacter turicensis sp. nov., Cronobacter muytjensii sp. nov., Cronobacter dublinensis sp. nov. and Cronobacter genomospecies 1. 2007 BMC Evol. Biol. pmid:17439656
Sav T et al. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? 2007 Ren Fail pmid:17497463
Breborowicz A et al. Peritoneal effects of intravenous iron sucrose administration in rats. 2007 Transl Res pmid:17543848
pmid:17577885
Herzberg M et al. Hepatic microsomal enzyme induction and its evaluation in a clinical laboratory. 1977 Isr. J. Med. Sci. pmid:17578
Auerbach M and Rodgers GM Intravenous iron. 2007 N. Engl. J. Med. pmid:17611217
Agarwal R et al. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. 2007 Kidney Int. pmid:17622274
Vikrant S Optimum dosage regimen for iron sucrose. 2007 Kidney Int. pmid:17625585
Yew WS et al. Evolution of enzymatic activities in the enolase superfamily: L-talarate/galactarate dehydratase from Salmonella typhimurium LT2. 2007 Biochemistry pmid:17649980
Reed J et al. The safety of intravenous iron sucrose use in the elderly patient. 2007 Consult Pharm pmid:17658969
Shaheen FA et al. Effect of intravenous iron saccharate on the requirements of erythropoietin in hemodialysis patients. 2002 Apr-Jun Saudi J Kidney Dis Transpl pmid:17660651
Thomas J and Martinez A Blood conservation in the critically ill. 2007 Am J Health Syst Pharm pmid:17687066
Singh H et al. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. 2006 Clin J Am Soc Nephrol pmid:17699248
Bishu K and Agarwal R Acute injury with intravenous iron and concerns regarding long-term safety. 2006 Clin J Am Soc Nephrol pmid:17699372
Zager RA Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease. 2006 Clin J Am Soc Nephrol pmid:17699373
Tryfinopoulou P et al. Diversity of Shewanella population in fish Sparus aurata harvested in the Aegean Sea. 2007 J. Appl. Microbiol. pmid:17714405
Vindal V et al. GntR family of regulators in Mycobacterium smegmatis: a sequence and structure based characterization. 2007 BMC Genomics pmid:17714599
Breymann C Treatment of iron deficiency anaemia in pregnancy and postpartum with special focus on intravenous iron sucrose complex. 2005 J Med Assoc Thai pmid:17718296
Grzegorzewska AE [Administration of iron-containing drugs in non-dialyzed patients with chronic kidney disease]. 2007 Pol. Arch. Med. Wewn. pmid:17722476
Singh J and Gupta KP Induction of apoptosis by calcium D-glucarate in 7,12-dimethyl benz [a] anthracene-exposed mouse skin. 2007 J. Environ. Pathol. Toxicol. Oncol. pmid:17725531
Malindretos P et al. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran. 2007 Am. J. Nephrol. pmid:17804904
Olas B et al. D-glucaro 1,4-lactone and resveratrol as antioxidants in blood platelets. 2008 Cell Biol. Toxicol. pmid:17846905
Sato K [Drug-induced osteomalacia]. 2007 Clin Calcium pmid:17906405
Saluk-Juszczak J et al. Protective effects of D-glucaro-1,4-lactone against oxidative modifications in blood platelets. 2008 Nutr Metab Cardiovasc Dis pmid:17933501
Teschke O et al. Quorum sensing detected by atomic force microscopy imaging of corrals surrounding multicellular arrangement of bacteria. 2008 Microsc. Res. Tech. pmid:17943987
Toblli JE et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. 2007 J. Am. Coll. Cardiol. pmid:17950147
Francis GS and Kanderian A Anemia and heart failure a new pathway? 2007 J. Am. Coll. Cardiol. pmid:17950148
Wang S et al. Chemical reactions of vitamin C with intravenous-iron formulations. 2008 Nephrol. Dial. Transplant. pmid:17951305
pmid:17994454
Franco G et al. Behaviour of urinary D-glucaric acid excretion in surgical patients and anaesthesiology staff acutely exposed to isoflurane and nitrous oxide. 1991 Nov-Dec Med Lav pmid:1803214